Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 56Myelodysplastic Syndromes 14Leukemia 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Myeloproliferative Disorders 5Recurrence 4Leukemia, Myelomonocytic, Chronic 3Leukemia, Monocytic, Acute 3Burkitt Lymphoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myelomonocytic, Acute 2Leukemia, Biphenotypic, Acute 2Hematologic Neoplasms 2Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myeloid 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Lymphoid 1Leukemia, Erythroblastic, Acute 1Hodgkin Disease 1Disease 1Congenital Abnormalities 1Anemia, Refractory, with Excess of Blasts 1

Interventions

ibrutinib 8fludarabine 8fludarabine phosphate 7Cyclophosphamide 7Busulfan 6blinatumomab 5Rituximab 5Whole-Body Irradiation 4Tacrolimus 4Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4Melphalan 4Methotrexate 3Mesna 3Lenalidomide 3Bone Marrow Transplantation 3Bendamustine Hydrochloride 3thymoglobulin 2pirtobrutinib 2Vincristine 2Patient Reported Outcome Measures 2Doxorubicin 2Biopsy 2Behavior Therapy 2Alemtuzumab 2venetoclax 1tozasertib 1sargramostim 1romiplostim 1pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Lymphoid × CPX-351 × Clear all
NCT03575325 2024-12-12

Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
11 enrolled 12 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Lymphoid, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡